Maulik  Nanavaty net worth and biography

Maulik Nanavaty Biography and Net Worth

Maulik Nanavaty is our senior vice president and president, Neuromodulation, a position he has held since September 2011. In this role, he is responsible for developing and bringing to market innovative, less-invasive microelectronic implantable technologies used to treat chronic neuropathic pain and neurological diseases such as Parkinson’s disease and other chronic conditions. Prior to his current role, Mr. Nanavaty was our president of Boston Scientific Japan; he also served as vice president and general manager, Interventional Cardiology, Boston Scientific Japan. Mr. Nanavaty joined Boston Scientific in 2005 as vice president, corporate strategy, Boston Scientific Japan. Mr. Nanavaty is a member of our Global Council for Inclusion and is the executive sponsor of our SAIL employee resource group, which advances professional development, business growth and corporate citizenship for South Asian employees, patients, physicians and communities. Prior to joining Boston Scientific, Mr. Nanavaty spent 16 years working in various executive positions at Baxter International, Inc. and Baxter Japan. Mr. Nanavaty earned a Ph.D. in Pharmaceutical Sciences from the University of Illinois and an M.B.A. from the University of Chicago.

What is Maulik Nanavaty's net worth?

The estimated net worth of Maulik Nanavaty is at least $44,475.00 as of November 16th, 2023. Mr. Nanavaty owns 500 shares of Boston Scientific stock worth more than $44,475 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Nanavaty may own. Learn More about Maulik Nanavaty's net worth.

How do I contact Maulik Nanavaty?

The corporate mailing address for Mr. Nanavaty and other Boston Scientific executives is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. Boston Scientific can also be reached via phone at (508) 683-4000 and via email at [email protected]. Learn More on Maulik Nanavaty's contact information.

Has Maulik Nanavaty been buying or selling shares of Boston Scientific?

Maulik Nanavaty has not been actively trading shares of Boston Scientific within the last three months. Most recently, Maulik Nanavaty sold 78,192 shares of the business's stock in a transaction on Friday, May 28th. The shares were sold at an average price of $42.59, for a transaction totalling $3,330,197.28. Following the completion of the sale, the senior vice president now directly owns 166,869 shares of the company's stock, valued at $7,106,950.71. Learn More on Maulik Nanavaty's trading history.

Who are Boston Scientific's active insiders?

Boston Scientific's insider roster includes Kevin Ballinger (EVP), Supratim Bose (EVP), Daniel Brennan (CFO), Vance Brown (SVP), Arthur Butcher (EVP), Wendy Carruthers (SVP), Nelda Connors (Director), Keith Dawkins (EVP), Charles Dockendorff (Director), Jodi Eddy (SVP), Joseph Fitzgerald (EVP), Edward Ludwig (Director), Edward Ludwig (Director), Edward Mackey (EVP), Michael Mahoney (CEO), Ian Meredith (EVP), Jeffrey Mirviss (EVP), Jonathan Monson (CAO), Maulik Nanavaty (SVP), Scott Olson (SVP), Michael Phalen (EVP), David Pierce (EVP), Timothy Pratt (EVP), Desiree Ralls-Morrison (SVP), Meghan Scanlon (SVP), John Sorenson (SVP), Eric Thepaut (EVP), Xin Wang (SVP), and David Wichmann (Director). Learn More on Boston Scientific's active insiders.

Are insiders buying or selling shares of Boston Scientific?

During the last twelve months, insiders at the medical equipment provider sold shares 23 times. They sold a total of 507,193 shares worth more than $40,282,850.73. The most recent insider tranaction occured on December, 2nd when EVP Wendy Carruthers sold 6,983 shares worth more than $633,916.74. Insiders at Boston Scientific own 0.5% of the company. Learn More about insider trades at Boston Scientific.

Information on this page was last updated on 12/2/2024.

Maulik Nanavaty Insider Trading History at Boston Scientific

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/28/2021Sell78,192$42.59$3,330,197.28166,869View SEC Filing Icon  
8/28/2020Sell38,000$40.45$1,537,100.00
12/4/2019Sell9,623$44.08$424,181.84
11/4/2019Sell9,623$41.66$400,894.18View SEC Filing Icon  
10/3/2019Sell9,623$39.25$377,702.75View SEC Filing Icon  
8/29/2019Sell34,035$42.65$1,451,592.75View SEC Filing Icon  
6/17/2019Sell3,039$40.46$122,957.94View SEC Filing Icon  
5/15/2019Sell3,038$36.74$111,616.12View SEC Filing Icon  
4/15/2019Sell3,039$37.81$114,904.5953,299View SEC Filing Icon  
3/15/2019Sell3,038$40.11$121,854.18View SEC Filing Icon  
2/15/2019Sell3,039$40.32$122,532.48View SEC Filing Icon  
1/15/2019Sell3,038$35.46$107,727.48View SEC Filing Icon  
11/16/2018Sell23,458$37.28$874,514.24View SEC Filing Icon  
2/9/2018Sell15,568$25.38$395,115.84View SEC Filing Icon  
8/31/2017Sell57,031$27.28$1,555,805.68View SEC Filing Icon  
8/30/2017Sell27,031$27.08$731,999.48View SEC Filing Icon  
5/29/2015Sell71,558$18.52$1,325,254.16View SEC Filing Icon  
See Full Table

Maulik Nanavaty Buying and Selling Activity at Boston Scientific

This chart shows Maulik Nanavaty's buying and selling at Boston Scientific by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Boston Scientific Company Overview

Boston Scientific logo
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Read More

Today's Range

Now: $88.95
Low: $87.25
High: $89.67

50 Day Range

MA: $88.31
Low: $83.62
High: $91.54

2 Week Range

Now: $88.95
Low: $54.96
High: $91.93

Volume

15,881,501 shs

Average Volume

6,000,576 shs

Market Capitalization

$131.10 billion

P/E Ratio

73.51

Dividend Yield

N/A

Beta

0.8